The PD-L1 expression is determined by the LifeTracDx ® blood test, which captures Circulating Tumor Cells (CTCs) and Cancer Associated Macrophage-Like cells (CAMLs) by staining the cells for PD ...
A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract ...
Immunotherapy is key for triple-negative breast cancer, but a new study finds Black women are receiving it less often than White women.
When used in conjunction with the PD-L1 IHC 28-8 pharmDx as a companion test, in the European Union: (a) resectable NSCLC patients with PD-L1 expression ≥1% and at high risk of recurrence may be ...
Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications Agilent Technologies Inc. (NYSE: A) today ...
"LLMs, fine-tuned with high-quality labeled data, accurately extracted complex PD-L1 test details from EHRs despite considerable variability in cancer type, documentation and time," reported the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback